The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF

Respiratory Medicine

Volumn 104, Issue 2, 2010, Pages 296-304

  Swigris, Jeffrey J ^a   Brown, Kevin K ^a   Behr, Juergen ^b   du Bois, Roland M ^a   King, Talmadge E ^c   Raghu, Ganesh ^d   Wamboldt, Frederick S ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Interstitial lung disease; Minimum important difference; Pulmonary fibrosis; Quality of life; Validity

Indexed keywords

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DYSPNEA; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; VALIDITY; AGED; ANALYSIS OF VARIANCE; FEMALE; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; VALIDATION STUDY;

AGED; ANALYSIS OF VARIANCE; DYSPNEA; FEMALE; HEALTH STATUS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS;

EID: 73849145996     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.09.006     Document Type: Article

References (25)

1. Swigris J.J., Gould M.K., and Wilson S.R. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 127 (2005) 284-294
2. Nishiyama O., Taniguchi H., Kondoh Y., et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor?. Respir Med 99 (2005) 408-414
3. Abrams D. Analysis of a life-satisfaction index. J Gerontol 24 (1976) 470
4. Swigris J.J., Kuschner W.G., Jacobs S.S., Wilson S.R., and Gould M.K. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 60 (2005) 588-594
5. King Jr. T.E., Behr J., Brown K.K., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177 (2008) 75-81
6. Joint Statement of the American Thoracic Society and the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 161 (2000) 646-664
7. Joint Statement of the American Thoracic Society and European Respiratory Society. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
8. Ware Jr. J., Sherbourne C., and The M.O.S. 36-item short-form health survey (SF-36). I. Coceptual framework and item selection. Med Care 30 (1992) 473-483
9. Jones P., Quirk F., and Baveystock C. The St. George's respiratory questionnaire. Respir Med 85 (1991) 25-31
10. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
11. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 22 (1951) 293-296
12. Kosinski M., Zhao S.Z., Dedhiya S., Osterhaus J.T., and Ware Jr. J.E. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43 (2000) 1478-1487
13. Kerlinger F. Foundations of behavioral research (1973), Holt, Rinehart, and Winston, New York
14. Witek Jr. T.J., and Mahler D.A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 21 (2003) 267-272
15. Wyrwich K., Nienaber N., Tierney W., and Wolinsky F. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 37 (1999) 469-478
16. Wyrwich K., Tierney W., and Wolinsky F. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52 (1999) 861-873
17. Hays R.D., Farivar S.S., and Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2 (2005) 63-67
18. Walters S.J., and Brazier J.E. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 1 (2003) 4
19. Norman G.R., Sloan J.A., and Wyrwich K.W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41 (2003) 582-592
20. Puhan M.A., Frey M., Buchi S., and Schunemann H.J. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 6 (2008) 46
21. Tomioka H., Imanaka K., Hashimoto K., and Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis-cross-sectional and longitudinal study. Intern Med 46 (2007) 1533-1542
22. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 56 (2001) 880-887
23. Jones P.W. St. George's respiratory questionnaire: MCID. COPD 2 (2005) 75-79
24. Du Bois R.M., Albera C., Costabel U., et al. Categorical declines in percent predicted forced vital capacity are associated with a graded risk of death in patients with idiopathic pulmonary fibrosis. Chest 134 (2008) S20003
25. Zappala C., Latsi P., Nicholson A.C., and Wells A.U. Marginal declines in FVC levels are associated with increased mortality in idiopathic pulmonary fibrosis. Thorax 175 (2007) A143